FULGENT GENETICS, INC. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
FULGENT GENETICS, INC. (FLGT) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $438.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2026-07-30
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2026-06-30 was -$2.17M, a 937.07% decline year-over-year.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2026-03-31 was $2.61M, a 12.23% increase year-over-year.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2025-06-30 was $259.00K, a 488.64% increase year-over-year.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2025-03-31 was $2.32M, a 51.00% decline year-over-year.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2025 was $1.69M, a 6.20% decline from fiscal 2024.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2024 was $1.81M, a 0.39% increase from fiscal 2023.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2023 was $1.80M, a 39.81% decline from fiscal 2022.
- FULGENT GENETICS, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2022 was $2.99M, a 178.05% increase from fiscal 2021.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $438.00K 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | $2.61M 10-Q · filed 2026-05-01 | |||
| 2025-12-31 | $1.69M 10-K · filed 2026-02-27 | |||
| 2025-06-30 | $259.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.58M 10-Q · filed 2026-07-30 | $1.90M derived: sum of 3 quarters · filed 2026-07-30 | -$396.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.32M 10-Q · filed 2026-05-01 | $1.64M derived: sum of 2 quarters · filed 2026-05-01 | -$655.00K derived: sum of 3 quarters · filed 2026-05-01 | -$611.00K derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | -$682.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$2.98M derived: sum of 2 quarters · filed 2026-02-27 | -$2.93M derived: sum of 3 quarters · filed 2026-02-27 | $1.81M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$2.25M derived: sum of 2 quarters · filed 2024-11-08 | $2.49M 10-Q · filed 2024-11-08 | $3.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $4.78M 10-Q · filed 2024-08-02 | $5.29M derived: sum of 3 quarters · filed 2026-02-27 | $2.86M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $4.74M 10-Q · filed 2025-05-02 | $5.25M derived: sum of 2 quarters · filed 2026-02-27 | $2.81M derived: sum of 3 quarters · filed 2026-02-27 | $4.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $511.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$1.93M derived: sum of 2 quarters · filed 2026-02-27 | -$738.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.80M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$1.25M derived: sum of 2 quarters · filed 2024-11-08 | $1.29M 10-Q · filed 2024-11-08 | $2.59M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $3.73M 10-Q · filed 2024-08-02 | $5.02M derived: sum of 3 quarters · filed 2025-02-28 | $4.56M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $2.54M 10-Q · filed 2024-05-03 | $3.84M derived: sum of 2 quarters · filed 2025-02-28 | $3.37M derived: sum of 3 quarters · filed 2025-02-28 | $3.47M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $831.00K derived: sum of 2 quarters · filed 2025-02-28 | $935.00K derived: sum of 3 quarters · filed 2025-02-28 | $2.99M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$468.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$364.00K derived: sum of 2 quarters · filed 2023-11-03 | $1.69M 10-Q · filed 2023-11-03 | $486.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $2.16M 10-Q · filed 2023-08-04 | $954.00K derived: sum of 3 quarters · filed 2024-02-28 | $2.49M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.05M 10-Q · filed 2023-05-05 | $850.00K derived: sum of 2 quarters · filed 2024-02-28 | $2.39M derived: sum of 3 quarters · filed 2024-02-28 | $2.33M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $333.00K derived: sum of 2 quarters · filed 2024-02-28 | $274.00K derived: sum of 3 quarters · filed 2024-02-28 | $1.07M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.48M derived: sum of 2 quarters · filed 2022-11-07 | $2.28M 10-Q · filed 2022-11-07 | $2.86M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $742.00K 10-Q · filed 2022-08-04 | $1.32M derived: sum of 3 quarters · filed 2023-02-28 | $3.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $801.00K 10-Q · filed 2022-05-05 | $1.38M derived: sum of 2 quarters · filed 2023-02-28 | $3.71M derived: sum of 3 quarters · filed 2023-02-28 | $4.16M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $580.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.90M derived: sum of 2 quarters · filed 2023-02-28 | $3.36M derived: sum of 3 quarters · filed 2023-02-28 | $3.40M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.78M derived: sum of 2 quarters · filed 2021-11-09 | $2.82M 10-Q · filed 2021-11-09 | $2.50M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $497.00K 10-Q · filed 2021-08-10 | $174.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.05M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $43.00K 10-Q · filed 2021-05-07 | -$280.00K derived: sum of 2 quarters · filed 2022-02-28 | $595.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $552.00K derived: sum of 2 quarters · filed 2022-02-28 | $557.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $875.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $880.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $5.00K 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $85.00K 10-K · filed 2020-03-13 | ||
| 2018-09-30 | $73.00K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |